CytoDyn to Hold Webcast and Live Q/A on January 13

NEXT STORY
Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease
PREV STORY
Monthly information on share capital and company voting rights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Cell Therapy Market Clinical Trials Forecast 2028

author_avatar
NASDAQ Market News

Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019

author_avatar
NASDAQ Market News

RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO

author_avatar
NASDAQ Market News